Drug Profile


Alternative Names: CI 1042; DI 1520; ONYX-015

Latest Information Update: 19 Feb 2008

Price : $50

At a glance

  • Originator Onyx Pharmaceuticals
  • Developer Onyx Pharmaceuticals; Pfizer
  • Class Antineoplastics; Oncolytic viruses
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Barrett's oesophagus; Cancer; Cancer metastases; Chemoprevention; Colorectal cancer; Head and neck cancer; Liver cancer; Oropharyngeal dysplasia; Ovarian cancer; Pancreatic cancer

Most Recent Events

  • 23 Jun 2003 Discontinued - Phase-II for Head and neck cancer in United Kingdom (Intratumoural)
  • 23 Jun 2003 Discontinued - Phase-II for Head and neck cancer in Canada (Intratumoural)
  • 23 Jun 2003 Discontinued - Phase-I for Barrett's oesophagus in USA (Intraluminal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top